CN113336862A - 一种抗多发性硬化的重组蛋白及其制备方法和用途 - Google Patents
一种抗多发性硬化的重组蛋白及其制备方法和用途 Download PDFInfo
- Publication number
- CN113336862A CN113336862A CN202110759727.8A CN202110759727A CN113336862A CN 113336862 A CN113336862 A CN 113336862A CN 202110759727 A CN202110759727 A CN 202110759727A CN 113336862 A CN113336862 A CN 113336862A
- Authority
- CN
- China
- Prior art keywords
- multiple sclerosis
- hsp65
- recombinant protein
- 6mog
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Rehabilitation Therapy (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Transplantation (AREA)
Abstract
Description
Claims (10)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110759727.8A CN113336862B (zh) | 2021-07-05 | 2021-07-05 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
AU2021290241A AU2021290241B2 (en) | 2021-07-05 | 2021-12-21 | Recombinant protein capable of resisting multiple sclerosis and preparation method and application thereof |
NL2030391A NL2030391B1 (en) | 2021-07-05 | 2022-01-02 | Recombinant protein capable of resisting multiple sclerosis and preparation method and application thereof |
PCT/CN2022/082141 WO2023279771A1 (zh) | 2021-07-05 | 2022-03-22 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
JP2022528137A JP7370110B2 (ja) | 2021-07-05 | 2022-03-22 | 多発性硬化症耐性の組み換えタンパク質およびその調製方法並びに用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110759727.8A CN113336862B (zh) | 2021-07-05 | 2021-07-05 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113336862A true CN113336862A (zh) | 2021-09-03 |
CN113336862B CN113336862B (zh) | 2022-03-01 |
Family
ID=77482761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110759727.8A Active CN113336862B (zh) | 2021-07-05 | 2021-07-05 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP7370110B2 (zh) |
CN (1) | CN113336862B (zh) |
AU (1) | AU2021290241B2 (zh) |
NL (1) | NL2030391B1 (zh) |
WO (1) | WO2023279771A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2030391B1 (en) * | 2021-07-05 | 2022-12-30 | Inst Of Zoology Guangdong Academy Of Sciences | Recombinant protein capable of resisting multiple sclerosis and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001031037A2 (en) * | 1999-10-27 | 2001-05-03 | Yeda Research And Development Co. Ltd. | Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases |
US20060024334A1 (en) * | 2001-12-05 | 2006-02-02 | Mark Larche | Immunotherapeutic methods and systems |
CN101687019A (zh) * | 2007-04-24 | 2010-03-31 | 迪亚米德治疗股份公司 | 用于治疗自身免疫性疾病和癌症的药物和方法 |
CN102388307A (zh) * | 2008-11-12 | 2012-03-21 | 耶达研究与发展有限公司 | 多发性硬化的诊断 |
CN105992950A (zh) * | 2013-12-19 | 2016-10-05 | 欧普萨治疗股份有限公司 | T 细胞表位表达谱分析、制备 t 细胞组合物以及治疗疾病的方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008500006A (ja) * | 2003-05-21 | 2008-01-10 | バイオテック トゥールス ソシエテ アノニム | ペプチド複合体 |
US20050031649A1 (en) * | 2003-08-06 | 2005-02-10 | Yongli Yu | Recombinant fusion proteins comprising BCG heat shock protein 65 and the epitope of MUC1 |
CN1831012A (zh) * | 2006-01-12 | 2006-09-13 | 中国药科大学 | 一种免佐剂具有防治人胰岛素依赖型糖尿病作用的免疫调节剂 |
WO2007094003A2 (en) * | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
CN105296408A (zh) * | 2015-04-01 | 2016-02-03 | 中国药科大学 | 一种新型抗i型糖尿病的重组乳酸菌及其应用 |
CN105254765A (zh) * | 2015-10-10 | 2016-01-20 | 江汉大学 | 重组蛋白MOG35-55-I-Abβ1-α1及其基因和应用 |
WO2018188730A1 (en) * | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Rna for treatment of autoimmune diseases |
CN108611310A (zh) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建 |
US20210169904A1 (en) * | 2018-07-03 | 2021-06-10 | University Of Florida Research Foundation, Incorporated | Microparticle systems and their use for the treatment of multiple sclerosis |
CN113336862B (zh) * | 2021-07-05 | 2022-03-01 | 广东省科学院动物研究所 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
-
2021
- 2021-07-05 CN CN202110759727.8A patent/CN113336862B/zh active Active
- 2021-12-21 AU AU2021290241A patent/AU2021290241B2/en active Active
-
2022
- 2022-01-02 NL NL2030391A patent/NL2030391B1/en active
- 2022-03-22 WO PCT/CN2022/082141 patent/WO2023279771A1/zh unknown
- 2022-03-22 JP JP2022528137A patent/JP7370110B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001031037A2 (en) * | 1999-10-27 | 2001-05-03 | Yeda Research And Development Co. Ltd. | Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases |
US20120172297A1 (en) * | 1999-10-27 | 2012-07-05 | Avraham Ben-Nun | Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases |
US20060024334A1 (en) * | 2001-12-05 | 2006-02-02 | Mark Larche | Immunotherapeutic methods and systems |
CN101687019A (zh) * | 2007-04-24 | 2010-03-31 | 迪亚米德治疗股份公司 | 用于治疗自身免疫性疾病和癌症的药物和方法 |
CN102388307A (zh) * | 2008-11-12 | 2012-03-21 | 耶达研究与发展有限公司 | 多发性硬化的诊断 |
CN105992950A (zh) * | 2013-12-19 | 2016-10-05 | 欧普萨治疗股份有限公司 | T 细胞表位表达谱分析、制备 t 细胞组合物以及治疗疾病的方法 |
Non-Patent Citations (5)
Title |
---|
ALYRIA TEIXEIRA DIAS等: ""Different MOG35–55 concentrations induce distinguishable inflammation through early regulatory response by IL-10 and TGF-b in mice CNS despite unchanged clinical course"", 《CELLULAR IMMUNOLOGY》 * |
SELMAJ, K等: ""EXPRESSION OF HEAT-SHOCK PROTEIN-65 BY OLIGODENDROCYTES INVIVO AND INVITRO - IMPLICATIONS FOR MULTIPLE-SCLEROSIS"", 《NEUROLOGY》 * |
SOFIA FERNANDA GONÇALVES ZORZELLA-PEZAVENTO等: ""pVAXhsp65 Vaccination Primes for High IL-10 Production and Decreases Experimental Encephalomyelitis Severity"", 《JOURNAL OF IMMUNOLOGY RESEARCH》 * |
WALTER.S: ""WP_003402236"", 《GENBANK》 * |
张遥: ""抗髓鞘少突胶质细胞糖蛋白抗体生物学特性研究"", 《中国优秀博硕士学位论文全文数据库(博士)医药卫生科技辑》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2030391B1 (en) * | 2021-07-05 | 2022-12-30 | Inst Of Zoology Guangdong Academy Of Sciences | Recombinant protein capable of resisting multiple sclerosis and preparation method and application thereof |
WO2023279771A1 (zh) * | 2021-07-05 | 2023-01-12 | 广东省科学院动物研究所 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
JP7370110B2 (ja) | 2021-07-05 | 2023-10-27 | 広東省科学院動物研究所 | 多発性硬化症耐性の組み換えタンパク質およびその調製方法並びに用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2023279771A1 (zh) | 2023-01-12 |
CN113336862B (zh) | 2022-03-01 |
JP7370110B2 (ja) | 2023-10-27 |
JP2023531842A (ja) | 2023-07-26 |
AU2021290241A1 (en) | 2023-01-19 |
NL2030391B1 (en) | 2022-12-30 |
AU2021290241B2 (en) | 2023-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190216898A1 (en) | Interleukin Combination and Use Thereof | |
US20090155269A1 (en) | Mesothelin antibody protein fusions and methods of use | |
ES2199932T3 (es) | Poxvirus recombinante y vacuna estreptococica que contiene proteina m. | |
CN111533812B (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
BR112020023642A2 (pt) | variante de antígeno de vírus de varicela zoster e uso da mesma | |
CN113336862B (zh) | 一种抗多发性硬化的重组蛋白及其制备方法和用途 | |
TW200902049A (en) | Fusion protein | |
WO2020220846A1 (zh) | 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用 | |
AU2021269320A1 (en) | Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a | |
EP3515929B1 (en) | Hepatitis b therapeutic vaccines | |
AU2017229991A1 (en) | Antigen-binding fusion proteins with modified HSP70 domains | |
US20060127418A1 (en) | Composition containing Leishmania Lip2a | |
CN101376887A (zh) | 猪口蹄疫重组免疫复合肽的制备方法及应用 | |
WO2022105880A1 (zh) | 融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用 | |
WO2005061531A1 (fr) | Proteine de fusion superantigene utilisee en therapie antitumorale et sa preparation | |
JPWO2006126682A1 (ja) | アルツハイマー病の予防・治療用ワクチン | |
Chu et al. | A single codon optimization enhances recombinant human TNF-α vaccine expression in Escherichia coli | |
US20030049797A1 (en) | Hybrid proteins for autoimmune disease | |
AU778957B2 (en) | Bacterial membrane fractions with adjuvant effect | |
EP0502016A1 (en) | NEW VACCINE. | |
CN113318225B (zh) | 肿瘤免疫增强剂及其制法和应用 | |
NZ519371A (en) | Immunomodulatory constructs and their uses | |
CN101011568A (zh) | 一种具有防治2型糖尿病作用的免疫调节剂 | |
CN107281487B (zh) | 一种兽用疫苗佐剂 | |
RU2782422C2 (ru) | Терапевтическая противораковая неоэпитопная вакцина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Yunxiao Inventor after: Rao Junhua Inventor after: Cao Dainan Inventor after: Peng Zhen Inventor after: Zhang Libiao Inventor after: Li Bihai Inventor after: He Xiangyang Inventor after: Ji Fang Inventor before: Sun Yunxiao Inventor before: Rao Junhua Inventor before: Peng Zhen Inventor before: Zhang Libiao Inventor before: Li Bihai Inventor before: He Xiangyang Inventor before: Ji Fang |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |